AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Feb 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-02-12

Reporting Person: Do Hung (Chief Science Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-12	Common Stock	M	6300	$8.61	Acquired	527455	Direct
2020-02-12	Common Stock	M	29148	$6.10	Acquired	556603	Direct
2020-02-12	Common Stock	M	17652	$5.13	Acquired	574255	Direct
2020-02-12	Common Stock	S	63356	$11.0067	Disposed	510899	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-12	Stock Options (right to buy)	$8.61	M	6300	Disposed	2025-01-02	Common Stock (6300)	Direct
2020-02-12	Stock Options (right to buy)	$6.10	M	29148	Disposed	2026-06-15	Common Stock (29148)	Direct
2020-02-12	Stock Options (right to buy)	$5.13	M	17652	Disposed	2027-01-03	Common Stock (17652)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.00 to $11.03 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of the options were fully vested and exercisable as of February 12, 2020.

F4: As of February 12, 2020, 45,812 options were fully vested and exercisable and 4,188 remained unvested from this grant.

F5: As of February 12, 2020, 20,594 options were fully vested and exercisable and 16,191 remained unvested from this grant.